p53 protein overexpression in relation to risk factors for breast cancer

American Journal of Epidemiology

Volumn 144, Issue 10, 1996, Pages 924-933

  Van Der Kooy, Karin ^a   Rookus, Matti A ^a   Peterse, Hans L ^a   Van Leeuwen, Flora E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

breast neoplasms; immunohistochemistry; protein p53; risk factors

Indexed keywords

MONOCLONAL ANTIBODY; ORAL CONTRACEPTIVE AGENT; PROTEIN P53;

ADULT; AGE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACTATION; MAJOR CLINICAL STUDY; NETHERLANDS; ORAL CONTRACEPTION; PROTEIN EXPRESSION; RISK FACTOR;

EID: 0029800828     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a008862     Document Type: Article

References (50)

1. Kelsey JL. Breast cancer epidemiology: summary and future directions. Epidemiol Rev 1993;15:256-63.
2. LiVolsi VA, Kelsey JL, Fischer DB, et al. Effect of age at first childbirth on risk of developing specific histologic subtype of breast cancer. Cancer 1982;49:1937-40.
3. Habel LA, Stanford JL. Hormone receptors and breast cancer. Epidemiol Rev 1993;15:209-19.
4. Olsson H, Borg A, Ferno M, et al. Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones. J Natl Cancer Inst 1991;83:1483-7.
5. Treurniet HF, Rookus MA, Peterse HL, et al. Differences in breast cancer risk factors to neu (c-erbB-2) protein overexpression of the breast tumor. Cancer Res 1992;52:2344-5.
6. Harlan LC, Coates RJ, Block G, et al. Estrogen receptor status and dietary intakes in breast cancer patients. Epidemiology 1993;4:25-31.
7. Nasca PC, Liu S, Baptiste MS, et al. Alcohol consumption and breast cancer: estrogen receptor status and histology. Am J Epidemiol 1994;140:980-7.
8. Van de Vijver MJ. Molecular genetic changes in human breast cancer. Adv Cancer Res 1993;61:25-56.
9. Allred DC, Elledge R, Clark GM, et al. The p53 tumor suppressor gene in human breast cancer. In: Dickson R, Lippman M, eds. Mammary tumorigenesis and malignant progression. Boston, MA: Kluwer Academic Publisher, 1994: 63-77.
10. Smith HS. Tumor-suppressor genes in breast cancer progression. In: Dickson R, Lippman M, eds. Mammary tumorigenesis and malignant progression. Boston, MA: Kluwer Academic Publisher, 1994:79-96.
11. Selter H, Montenarh M. The emerging picture of p53. Int J Biochem 1994;26:145-54.
12. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene; clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
13. Sommer SS, Cunningham J, McGovern RM, et al. Pattern of p53 gene mutations in breast cancers of women of the Midwestern United States. J Natl Cancer Inst 1992;84:246-52.
14. Sasa M, Kondo K, Komaki K, et al. Frequency of spontaneous p53 mutations (CpG site) in breast cancer in Japan. Breast Cancer Res Treat 1993;27:247-52.
15. Blaszyk H, Vaughn CB, Hartmann A, et al. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet 1994;343:1195-7.
16. Biggs PJ, Warren W, Venitt S, et al. Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer. Mutagenesis 1993;8:275-83.
17. Rookus MA, van Leeuwen FE for the Netherlands Oral Contraceptive and Breast Cancer Study Group. Oral contraceptives and risk of breast cancer in women aged 20-54 years. Lancet 1994;344:844-51.
18. Top B, Mooi WJ, Klaver SG, et al. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer 1995;64:83-91.
19. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? - revisited! J Pathol 1994;172:1-4.
20. Hosmer DW, Lemeshow A. Applied logistic regression. New York, NY: John Wiley & Sons, 1989.
21. Prosser J, Thompson AM, Cranston G, et al. Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene 1990;5:1573-9.
22. Malone KE, Daling JR, Weiss NS. Oral contraceptives in relation to breast cancer risk. Epidemiol Rev 1993;15:80-97.
23. U. K. National Case-Control Study Group. Oral contraceptive use and breast cancer risk in young women. Lancet 1989;1: 973-82.
24. White E, Malone KE, Weiss NS, et al. Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst 1994;86:505-14.
25. Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995;87:827-35.
26. Newcomb PA, Storer BE, Longnecker MP, et al. Lactation and reduced risk of premenopausal breast cancer. N Engl J Med 1994;330:81-7.
27. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36-47.
28. Davidhoff AM, Herndon JE, Glover NS, et al. Relation between p53 expression and established prognostic factors in breast cancer. Surgery 1991;110:259-64.
29. Tsuda H, Iwaya K, Fukutomi T, et al. p53 mutations and c-erbB-2 amplification in intraductal and invasive carcinomas of high histologic grade. Jpn J Cancer Res 1993;84:394-401.
30. Mazars R, Spinardi L, BenCheikh M, et al. p53 mutations occur in aggressive breast cancer. Cancer Res 1992;52: 3918-23.
31. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84: 845-55.
32. Prosser J, Elder PA, Condie A, et al. Mutations in p53 do not account for heritable breast cancer: a study in five affected families. Br J Cancer 1991;63:181-4.
33. Coles C, Condie A, Chetty U, et al. p53 mutations in breast cancer. Cancer Res 1992;52:5291-8.
34. Glebov OK, McKenzie KE, White CA, et al. Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res 1994;54:3703-9.
35. Warren W, Eeles RA, Ponder BA, et al. No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families. Oncogene 1992;7:1043-6.
36. Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 gene mutations in breast cancer. Cancer Res 1992;52:2984-6.
37. Srivastava S, Zou Z, Pirollo K, et al. Germ line transmission of mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990;48:747-9.
38. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
39. Fisher CJ, Gillett CE, Vojtesek B, et al. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 1994;69: 26-31.
40. Pietenpol JA, Vogelstein B. No room at the p53 inn. Nature 1993;365:17-18.
41. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A 1992;89:7262-6.
42. Andersen TI, Holm R, Nesland JM, et al. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993;68:540-8.
43. Marchetti A, Buttitta F, Pellegrini S, et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993;53:4665-9.
44. Davidoff AM, Kerns BJM, Iglehart JD, et al. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991;51:2605-10.
45. Varley JM, Brammer WJ, Lane DP, et al. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 1991;6:413-21.
46. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329: 1318-27.
47. Holmberg L, Lund E, Bergstrom R, et al. Oral contraceptives and prognosis in breast cancer: effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. Eur J Cancer 1994;30A:351-4.
48. Schönbron I, Nischan P, Ebeling K. Oral contraceptives use and the prognosis of breast cancer. Breast Cancer Res Treat 1994;30:283-92.
49. Ranstam J, Olsson H, Garne JP, et al. Survival in breast cancer and age at start of oral contraceptive usage. Anticancer Res 1991;11:2043-6.
50. Wingo PA, Austin H, Kosinski A, et al. Five-year survival of women with breast cancer according to prior use of oral contraceptives. In: Li JJ, Li SA, Gustafsson JA, et al., eds. Hormonal carcinogenesis II. New York, NY: Springer Verlag 1996:360-4.